NinePointTwo Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

NinePointTwo Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$364K	Hold	21,687	–	–	0.14%	78
2023 Q3	$253K	Buy	21,687 +5,079	+31%	+$67.9K	0.1%	114
2023 Q2	$223K	Buy	+16,608	New	+$239K	0.09%	183
2023 Q1	–	Sell	-12,777	Closed	-$237K	–	271
2022 Q4	$237K	Buy	+12,777	New	+$197K	0.1%	76

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

NinePointTwo Capital's CPRX Position: Q4 2023 in Review

NinePointTwo Capital held its Catalyst Pharmaceutical (CPRX) position steady in Q4 2023 at 21,687 shares worth $364K. The position accounts for 0.14% of the portfolio, ranked #78.

NinePointTwo Capital first reported a position in CPRX in Q4 2022 and has held it in 4 quarters since. 259 funds tracked by Wall St. Rank hold CPRX as of Q4 2023.

NinePointTwo Capital held 21,687 shares of Catalyst Pharmaceutical worth $364K as of Q4 2023.
NinePointTwo Capital left its Catalyst Pharmaceutical share count unchanged in Q4 2023.
Catalyst Pharmaceutical made up 0.14% of NinePointTwo Capital's portfolio in Q4 2023, its #78 holding.
NinePointTwo Capital first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 4 quarters since.
259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.